A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0148-0000-0106 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs NN 1952 (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 11 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 10 Dec 2009 New trial record.